



TML: CS: BDM-43/ 2022-23

28<sup>th</sup> July, 2022

Listing Department,  
**BSE Limited**,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Listing Department,  
**National Stock Exchange of India Ltd.**  
"Exchange Plaza",  
Bandra – Kurla Complex,  
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

Meeting Commencement time : 10.30 A.M.  
Meeting Conclusion Time : 02:10 P.M.

The Board of Directors at its meeting held today, considered and approved the Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30<sup>th</sup> June, 2022.

A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30<sup>th</sup> June, 2022 is enclosed herewith.

This may be taken as compliance under the Listing Regulations.

Kindly acknowledge.

Thanking you,  
Yours faithfully,

For **THEMIS MEDICARE LIMITED**



**SANGAMESHWAR IYER**  
Company Secretary & Compliance Officer

## **Themis Medicare Limited**

**Corporate Office** : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104. India  
**Tel.** : 91-22-6760 7080 • **Fax** : 91-22-6760 7070 / 2874 6621  
**Regd. Office** : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat.  
**CIN No.:** L24110GJ1969PLC001590 • **Tel / Fax No.:** **Regd. Off.** : 0260 2431447 / 2430219  
• **E-mail** : themis@themismedicare.com • **Website** : www.themismedicare.com

# THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

## Statement of Unaudited Financial Results for the quarter ended 30th June 2022.

( Amount in INR Lakhs )

	Particulars	STANDALONE			
		Quarter Ended			Year Ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	9,443.51	7,979.72	11,250.35	39,461.41
2	Other Income	68.45	183.83	34.93	654.10
3	Total Income ( 1 + 2 )	9,511.96	8,163.55	11,285.28	40,115.51
4	Expenses :				
	(a) Cost of materials consumed	1,824.92	2,711.88	2,970.83	11,363.06
	(b) Purchases of stock-in-trade	798.58	587.74	838.18	3,144.76
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	337.33	(625.21)	342.21	306.12
	(d) Employee benefits expense	1,632.22	1,363.84	1,083.95	5,197.25
	(e) Finance Costs	225.75	192.78	266.91	877.36
	(f) Depreciation and amortisation expense	246.02	238.91	235.03	947.98
	(g) Other expenses	2,814.47	2,499.25	1,967.67	9,885.08
	Total expenses	7,879.29	6,969.19	7,704.78	31,721.61
5	Profit / (Loss) before exceptional items and tax (3 - 4)	1,632.67	1,194.36	3,580.50	8,393.90
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5 - 6)	1,632.67	1,194.36	3,580.50	8,393.90
8	Tax expense :				
	(a) Current Tax	463.00	300.00	650.00	1,675.00
	(b) Deferred Tax	6.32	139.45	257.14	563.13
9	Profit / (Loss) for the period (7 - 8)	1,163.35	754.91	2,673.36	6,155.77
10	Other Comprehensive Income :				
	(a i) Items that will not be reclassified to Profit & Loss	(10.65)	(10.67)	(10.64)	(42.59)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	2.68	2.69	2.68	10.72
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-
11	Total Comprehensive Income for the period (9 + 10)	1,155.38	746.93	2,665.40	6,123.90
12	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	920.03	920.03	919.40	920.03
13	Other Equity (Excluding Revaluation Reserve)				20,010.91
14	Earnings per share :				
	(a) Basic	12.64	8.21	29.08	66.91
	(b) Diluted	12.62	8.19	29.03	66.78



# THEMIS MEDICARE LTD

Statement of Unaudited Financial Results for the quarter ended 30th June 2022.

( Amount in INR Lakhs )

	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	9,443.51	7,979.72	11,250.35	39,461.41
2	Other Income	68.45	183.83	34.93	654.10
3	Total Income ( 1 + 2 )	9,511.96	8,163.55	11,285.28	40,115.51
4	Expenses :				
	(a) Cost of materials consumed	1,824.92	2,711.88	2,970.83	11,363.06
	(b) Purchases of stock-in-trade	798.58	587.74	838.18	3,144.76
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	337.33	(625.21)	342.21	306.12
	(d) Employee benefits expense	1,632.22	1,363.84	1,083.95	5,197.25
	(e) Finance Costs	225.77	192.82	266.91	877.45
	(f) Depreciation and amortisation expense	246.02	238.91	235.03	947.98
	(g) Other expenses	2,814.49	2,500.47	1,967.95	9,886.72
	Total expenses	7,879.33	6,970.45	7,705.06	31,723.34
5	Profit / (Loss) before exceptional items, share of Profit/(Loss) of associates and joint venture and tax (3 - 4)	1,632.63	1,193.10	3,580.22	8,392.17
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before share of Profit / (Loss) of associates and joint venture and tax (5 - 6)	1,632.63	1,193.10	3,580.22	8,392.17
8	Add: Share of Profit / (Loss) of associates and a joint venture for the period	577.01	241.32	446.73	1,134.03
9	Profit / (Loss) before tax (7 + 8)	2,209.64	1,434.42	4,026.95	9,526.20
10	Tax expense :				
	(a) Current Tax	463.00	300.00	650.00	1,675.00
	(b) Deferred Tax	6.32	139.45	257.14	563.13
11	Profit / (Loss) for the period (9 - 10)	1,740.32	994.97	3,119.81	7,288.07
	Attributable to :				
	Equity holders of the Parent	1,740.32	994.97	3,119.81	7,288.08
	Non - Controlling interests	-	-	-	(0.01)
12	Other Comprehensive Income :				
	(a i) Items that will not be reclassified to Profit & Loss	(10.65)	(10.67)	(10.64)	(42.59)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	2.68	2.69	2.68	10.72
	(a iii) Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method	(0.46)	(1.32)	(0.18)	(1.85)
	(b) Items that will be reclassified to Profit & Loss	(0.00)	(0.23)	1.02	(0.10)
13	Total Comprehensive Income for the period (11 + 12)	1,731.89	985.44	3,112.69	7,254.25
	Attributable to :				
	Equity holders of the Parent	1,731.89	985.44	3,112.69	7,254.26
	Non - Controlling interests	-	-	-	(0.01)
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	920.03	920.03	919.40	920.03
15	Other Equity (Excluding Revaluation Reserve)				24,411.70
16	Earnings per share :				
	(a) Basic	18.92	10.81	33.93	79.22
	(b) Diluted	18.88	10.79	33.88	79.07



**NOTES :**

- 1 ) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its meeting held on July 28, 2022.
- 2 ) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act , 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 3 ) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 4 ) The Company continues to closely monitor the impact of the COVID-19 pandemic on all aspects of its business, including how it has impacted and will impact its customers, employees, vendors and business partners. The management has exercised due care, in concluding on significant accounting judgements and estimates, inter-alia, recoverability of receivables, assessment for impairment of investments, intangible assets, inventory, based on the information available to date, both internal and external, while preparing the Company's financial results for the quarter ended 30th June, 2022.
- 5 ) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been notified in the Gazette of India. However, the date from which it will be implemented has reportedly not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- 6 ) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board  
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL  
(Managing Director & CEO )  
(DIN No. 00033353 )

Place : Mumbai  
Date : 28th July, 2022



**Raju P. Sardar**  
B.Com., F.C.A.

**R. P. Sardar & Co.**  
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,  
I. C. Colony, Borivali (West), Mumbai - 400 103.  
Tel.: +91-22-2893 3556 • Mobile : +91-98212 16687  
E-mail : rpsardar@gmail.com

**INDEPENDENT AUDITORS REVIEW REPORT ON THE QUARTERLY UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.**

**Review Report to  
The Board of Directors  
THEMIS MEDICARE LIMITED**

- 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **THEMIS MEDICARE LIMITED** ("the Company") for the Quarter ended on June 30, 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.*
- 2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.*
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.*
- 4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Indian Accounting Standard prescribed under section 133 of the Companies*



*Act, 2013 read with relevant Rules and other recognized accounting practices and policies thereon, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.*

**For R.P. Sardar & Co.**  
**Chartered accountants**  
**(Firm's Registration No. 109273W)**



*Raju P. Sardar*

**Raju P. Sardar**  
**(Proprietor)**  
**(Membership No. 037845)**

**Place:** Mumbai

**Date:** 28<sup>th</sup> July, 2022

**UDIN:** 2203784 SANTR VT8301



**Raju P. Sardar**  
B.Com., F.C.A.

**R. P. Sardar & Co.**  
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,  
I. C. Colony, Borivali (West), Mumbai - 400 103.  
Tel.: +91-22-2893 3556 • Mobile: +91-98212 16687  
E-mail : rpsardar@gmail.com

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.**

*Review Report to*  
*The Board of Directors*  
***THEMIS MEDICARE LIMITED***

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **THEMIS MEDICARE LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and the total comprehensive income of its associates for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Listing Regulations").*
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.*
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard required that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.*



*We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.*

4. *The Statement includes the results of the following entities:*

**Subsidiaries**

- a. *Carpo Medical Limited (UK)*
- b. *Themis lifestyle Private limited*
- c. *Artemis biotech Limited*

**Associates**

- a. *Gujarat Themis Biosys Limited*
- b. *Long Island Nutritionals Private Limited*

**Associate (Joint Venture)**

- a. *Richter Themis Medicare (India) Private Limited*

5. *Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed or that it contains any material misstatement.*

6. *The Statement includes the interim financial results of 2 Associates & 1 Joint Venture which have not been reviewed, whose interim financial results reflect total revenues of Rs.7,067.69 Lakhs, total net Profit after tax of Rs.2,113.60 Lakh and total comprehensive income of Rs.-2.00 Lakh for the quarter ended 30 June, 2022, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.*





*One subsidiary which is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles, generally accepted in the country and which have been audited by other auditor under generally accepted auditing standards applicable in the country. The Company's management has converted the financial statement of such subsidiary located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affair of such subsidiary located outside India is based on the report of the other auditor and the conversion adjustments prepared by the management of the Company and audited by us.*

*Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the financial results and other financial information certified by the Management.*

**For R.P. Sardar & Co.**  
**Chartered accountants**  
**(Firm's Registration No.-109273W)**



**Place: Mumbai**

**Date: 28<sup>th</sup> July, 2022**

**UDIN: 22037 845 ANTRMG6334**



**Raju P. Sardar**  
**(Proprietor)**  
**(Membership No. 037845)**